ACADIA Pharmaceuticals Inc. reiterated earnings guidance for the full year 2024. For the year, the company expects DAYBUE net product sales guidance in the range of $370 million to $420 million. NUPLAZID net product sales guidance in the range of $560 million to $590 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.12 USD | +0.83% | -0.79% | -51.84% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.84% | 2.48B | |
+56.08% | 58.06B | |
-5.83% | 40.53B | |
+37.52% | 38.99B | |
+13.19% | 26.7B | |
-12.01% | 26.56B | |
-21.55% | 18.98B | |
+1.19% | 12.17B | |
+23.12% | 12B | |
+26.36% | 11.92B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Acadia Pharmaceuticals Inc. Reiterates Earnings Guidance for the Full Year 2024